Navigation Links
Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer

WASHINGTON, April 17, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), announced today that it has named Paolo Baroldi , M.D., Ph.D. as its Senior Vice President and Chief Medical Officer.

Dr. Baroldi has over 30 years of clinical development experience in many therapeutic areas, including neurology and psychiatry.  He has been working in the role of acting Chief Medical Officer with Vanda since October 1, 2012.

"We welcome Paolo to Vanda and look forward to his leadership in strengthening our clinical organization," said Mihael H. Polymeropoulos , M.D., President and Chief Executive Officer of Vanda.

Dr. Baroldi previously served as the Senior Vice President and Chief Medical Officer of Vanda from July 2006 through January 2009.  He has served in senior clinical development positions at Galileo Research, Supernus Pharmaceuticals, Chiesi Farmaceutici SpA, and Novartis AG.

Dr. Baroldi holds M.D. and Ph.D. degrees from the University of Milan, Italy and is a member of the board of directors of Galileo Research. 


Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit

Company Contact

Jim Kelly
Senior Vice President  & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
2. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
(Date:10/9/2015)... PHILADELPHIA , Oct. 9, 2015 Governor ... a clinical stage biopharmaceutical company focused on developing T-cell ... new, high-paying jobs with a new expansion project. ... great news for the commonwealth as 110 new, high-paying ... Tom Wolf . "My budget proposal includes sustained ...
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... Leading ... study that aims to better understand the relationship between weight management and the microbiome. ... and more accurately from participants using an iPhone app. , The uBiome app is ...
(Date:10/8/2015)... , Oct. 8, 2015  ATCC, the premier global ... it has been selected by The Michael J. Fox ... lines to academic, pharmaceutical, and biotechnology organizations committed to ... the United States , and more than ... the United States , and more than ...
(Date:10/8/2015)... Texas , Oct. 8, 2015 The 2015 ... of The University of Texas at Dallas. Aziz Sancar ... UT Dallas in 1977, is one of ... how cells continuously monitor and repair damaged DNA on a molecular ... in molecular and cell biology from UT Dallas ...
Breaking Biology Technology:
... Integra Merger, IRVINE, California, October 24 IsoTis, ... announced that,it has adjourned the special meeting of stockholders ... IsoTis by Integra LifeSciences Holdings,Corporation (NASDAQ: IART ) ... as of August 6, 2007. The special meeting ...
... ALTO, Calif., Oct. 24 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... quarter 2007 financial results on Tuesday, November 6, 2007,following ... host an investor conference call and live audio webcast ... 6, 2007, at 5:00 p.m.,Eastern Time/2:00 p.m. Pacific Time. ...
... 24 /PRNewswire-FirstCall/ - Atrium Innovations Inc. (TSX:,ATB) will ... 10 a.m. Eastern,time on November 8, 2007. The ... third quarter results issued earlier the previous day.,Participants ... numbers:,416-644-3418, 514-807-8791 or 800-591-7539 or via the Company,s ...
Cached Biology Technology:
(Date:9/30/2015)... Calif. , Sept. 30, 2015  With nearly ... the number of new SCIs estimated to reach 12,500 ... Southern California Resource Services for Independent Living ... ILCs in California opening doors ... range of programs and services, notably assistive technology services ...
(Date:9/29/2015)... SUNNYVALE, Calif. , Sept. 29, 2015 ... technology improves employee productivity while also saving energy ... features such as Low Power Active Mode and embedded ... workplace transformation Fujitsu today shows that ... of new and refreshed models to its enterprise desktop ...
(Date:9/28/2015)... Sept. 28, 2015  The monitoring of vital ... body temperature, is an essential component of patient ... of deterioration in a patient,s condition. However, in ... are typically taken during routine observation rounds only ... patient deteriorates between these observation rounds, the warning ...
Breaking Biology News(10 mins):
... it will expand urea deep placement (UDP)a technology that doubles ... (ha) of rice land, reaching about 1.6 million farm families, ... is the insertion of large urea briquettes into the rice ... who use UDP can increase yields by 25% while using ...
... humile, is one of the most successful invasive species in ... to its native range in South America. A new study ... findings, from researchers at the University of Illinois and the ... the Proceedings of the National Academy of Sciences. The ...
... Richard D. Smith, Battelle Fellow at the U.S. Department ... of 50 outstanding leaders in the 2007 Scientific American 50. ... key contributors in science and technology. Smith shared the ... a colleague from UCLAs David Geffen School of Medicine, Desmond ...
Cached Biology News:
... vectors are designed for enhanced translation of cloned ... rabbit reticulocyte lysate. The maps for pCITE-2b(+) and ... following exceptions: pCITE-2b(+) is a 3793 bp plasmid; ... and Xcm I sites. Subtract 7 bp from ...
Biology Products: